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Abstract
Background: In order to minimise postoperative intraocular pressure (IOP) rise, after routine
uncomplicated cataract surgery, prophylaxis may be adopted. Currently, there are no specific
guidelines in this regard resulting in wide variation in practice across the UK. We sought to
document these variations through a questionnaire survey.
Methods: A questionnaire was sent to all consultant ophthalmic surgeons in the UK.
Results:  62.6% of surgeons did not use any IOP lowering agents. 37.4% surgeons routinely
prescribed some form of medication. The majority (86.8%) used oral diamox. 20.6% of surgeons
said they based their practice on evidence, 43.3% on personal experience, and 17.6% on unit policy.
Surprisingly, among the two groups of surgeons (those who gave routine prophylaxis, and those
who did not) the percentages of surgeons quoting personal experience, unit policy, or presence of
evidence was strikingly similar. The timing of the first postoperative IOP check varied from the
same day to beyond 2 weeks. Only 20.2% of surgeons had ever seen an adverse event related to
IOP rise; this complication is thus very rare.
Conclusion: This survey highlights a wide variation in the practice and postoperative management
of phacoemulsification cataract surgery. What is very striking is that there is a similar proportion
of surgeons in the diametrically opposite groups (those who give or do not give routine IOP
lowering prophylaxis) who believe that there practice is evidence based. The merits of this study
suggests that consideration must be given to drafting a uniform guideline in this area of practice.
Background
Phacoemulsification and intra-ocular lens implantation
(PhIOL) is one of the most cost-effective, elective surgical
interventions. In order to minimise postoperative intraoc-
ular pressure (IOP) rise, prophylaxis may be adopted.
Currently, there are no specific guidelines for prophylaxis
in uncomplicated cataract surgery. We studied current
prophylaxis practice in a UK-wide survey which showed
wide variation in prophylaxis practice.
Methods
We conducted a pilot, self-administered postal-based sur-
vey of the Scottish ophthalmic consultants. The results of
this survey suggested variation in prophylaxis practice for
IOP rise, duration until 1st  IOP monitoring, and
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management of elevated IOP following uncomplicated
phacoemulsification with intraocular lens implantation
with no coexisting comorbidity. This prompted us to
extend our enquiry across the U.K. We obtained the
names and addresses of ophthalmic consultants working
across the United Kingdom, from the Royal College of
Ophthalmologists, London. A questionnaire (Appendix
1) was sent to all the consultants between April and July
2003. The data were entered on a spreadsheet using
Microsoft Excel. Data was analysed using SPSS 11(SPSS
Inc, Chicago, IL).
Results
The questionnaire was sent to 834 ophthalmic surgeons,
and 515 (61.7%) responded. No reminders were sent. Ten
did not perform cataract surgery and their responses were
excluded from further analysis.
Routine use of IOP prophylaxis following uncomplicated 
phacoemulsification and lens implant surgery
Of the 505 surgeons, who performed cataract surgery, 316
(62.6%) did not use any IOP lowering agent following
uncomplicated phacoemulsification, and lens implant
surgery. The remaining 189 (37.4%) routinely prescribed
some form of medication for IOP prophylaxis.
Of the 189 surgeons who used some form of prophylaxis,
oral diamox was used by 164 (86.8%), and a topical agent
was used by 21 (11.1%). The remaining 4 (2.1%) sur-
geons used both.
Of the 168 surgeons who used oral diamox, 113 (67.2%),
gave only one dose, 41 (24.4%) gave two doses, 9 (5.3%)
gave three doses, and 5 (2.9%) gave four or more doses.
Of the 25 surgeons who used topical agents, 22 (88%)
gave only one dose, and 1 (4%) surgeon each gave 3, 5,
and 6 doses.
Basis of IOP prophylaxis practice
We questioned the surgeons about the basis of their prac-
tice using a forced choice selection of a) based on evi-
dence, b) personal experience, or c) as a matter of unit
policy. Surgeons were allowed to select more than one
option. Two hundred and ten (41.5%) surgeons did not
reply, 104 (20.6%) said their practice was based on evi-
dence, 219 (43.3%) said their practice was based on per-
sonal experience, and unit policy was the basis for 89
(17.6%). We analysed further the basis of practice, accord-
ing to whether routine prophylaxis was used or not, and
which drug was used. A total of 316 surgeons did not pre-
scribe IOP lowering agent routinely. Of these, 209 sur-
geons (66.1%) chose not to reply when asked about the
basis of their practice. Of the 107, who chose to reply, 42
(39.2%) said their practice was based on evidence, 74
(69.1%) said their practice was based on personal experi-
ence, and 22 (20.5%) on unit policy. One hundred and
eighty nine surgeons routinely used some form of IOP
lowering agent. Of these only one surgeon (0.5%) did not
reply, to the question regarding the basis of their practice.
Of the 188 who chose to reply, 62 (32.9%) said their prac-
tice was based on evidence, 124 (65.9%) said their prac-
tice was based on personal experience, and 43 (22.8%) on
unit policy. The difference in the proportion of surgeons
in the two groups choosing not to reply to this question is
significant (p < 0.001). Among the respondents, the per-
centages of surgeons quoting personal experience, unit
policy, or presence of evidence is strikingly similar (figure
1).
Time of first postoperative IOP check
The timing of the first postoperative IOP check varied.
Fifty-five surgeons (10.9%) reported the first IOP check
was carried out on the same day, 150 (29.7%) on the first
postoperative day, 105(20.8%) by the first week, 136
(26.9%) at 2 weeks, and 48 (9.5%) beyond 2 weeks. Nine
surgeons (1.8%) said they never check IOP routinely.
There was no significant difference in the timing of the
first postoperative check between the users and non-users
of IOP prophylaxis.
To assess whether the timing of postoperative IOP meas-
urement has any impact on the incidence of reported
adverse events, we looked at the following:
a) the various time points at which postoperative IOP
measurements were made amongst the two groups of sur-
geons (those who give routine prophylaxis versus those
who don't). (Table 1)
Basis of practice Figure 1
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b) the relation between the timing of first postoperative
IOP check and the reported experience with adverse
events. (Table 2)
There was no statistically significant association between
the timing of first IOP check, and the practice of giving
routine prophylaxis. Similarly, there was no statistically
significant association between the timing of first IOP
check, and the reported experience with adverse events.
Adverse event related to postoperative intraocular 
pressure elevation
One hundred and two surgeons (20.2%) had seen an
adverse event related to IOP rise, compared to 396
(78.4%) who had not. 7 (1.4%) surgeons did not answer
this question.
Of the 189 surgeons who routinely use IOP prophylaxis,
31 (16%) had encountered an adverse event in their prac-
tice, and 157 (83%) had not. Of the 316 surgeons who
did not routinely use any prophylaxis, 71 (22%) had seen
an adverse event, compared to 239 (75.6%) who had not.
The difference was not significant (p = 0.10). A variety of
adverse events were reported including corneal oedema,
central retinal vein occlusion, ocular pain, optic
neuropathy.
Discussion
Cataract extraction is one of the most commonly per-
formed and successful surgical procedures. This survey
highlights a wide variation in the practice in the
postoperative management of phacoemulsification cata-
ract surgery.
Raised intraocular pressure is one of the most common
complication following cataract surgery, requiring specific
treatment [1-6]. Many treatment strategies of blunting
acute post-op IOP spikes have been proposed, including
use of prophylactic intracameral cholinergic agents and
topical and systemic antiglaucoma medication [7-10].
However, this does not seem to eliminate spikes and
many have found their effect to be negligible compared to
a placebo [11-14]. The current literature on medical
prophylaxis is conflicting [15-18] Most of the antiglau-
coma agents used to prevent or lessen IOP increase
postoperatively have limitations. 87% of responders who
use IOP prophylaxis prefer oral Diamox over the topical
agents. Oral Diamox or, Acetazolamide, a systemic sul-
phonamide inhibitor of carbonic anhydrase enzyme,
reduces the flow of aqueous humor, thereby lowering the
IOP. Acute urinary retention amongst men with prostatic
enlargement and falls amongst the elderly may also occur
with oral Diamox. Less serious side effects include thirst,
drowsiness, polyuria and paraesthesia. This may result in
accidents in elderly patients who have just undergone
ocular surgery. More severe adverse reactions include fatal
aplastic anaemia, sulfaallergy cross sensitivity and acid
base disturbance [21].
Iopidine and Timoptol are the most common topical
agents used for post-op IOP prophylaxis as shown in the
survey. A number of clinical trials studying the effect of
pre and post-operative use of Apraclonidine and Timoptol
in reducing post-op rise have shown variable
results[8,9,12,14,17,18].
Our survey also demonstrates a wide variation in the tim-
ing of the first IOP check. Only 10.9 % of our responders
check IOP on the day of surgery. These patients do not
visit the hospital on the first postoperative day, which is
very convenient for them, and for overall majority of
patients, visual outcome is not compromised when rou-
tine next day review is omitted after phacoemulsification
surgery [19,20].
This reflects the relatively low frequency of severe IOP ele-
vation one day postoperatively, the self limiting nature of
IOP spikes and the tolerance of a healthy eye.
Table 1
Timing of first IOP check Surgeons give routine prophylaxis (n = 189) Surgeons do not give routine prophylaxis (n = 316)
Same Day 22 (11.6%) 33 (10.4%)
1st postop day 52 (27.5%) 98 (31.0%)
By 1st week 35 (18.5%) 70 (22.1%)
At 2 weeks 59 (31.2%) 77 (24.3%)
Beyond 2 weeks 17 (8.9%) 31 (9.8%)
Never 4 (2.1%) 5 (1.5%)
No reply 0 (0%) 2 (0.6%)
Legend: This table shows the timing of the first postoperative IOP check in the two groups of surgeons (those who routinely give or don't give 
prophylaxis). There is no statistical significant difference between the two groups.BMC Ophthalmology 2005, 5:24 http://www.biomedcentral.com/1471-2415/5/24
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This survey also showed that only 20.2% surgeons had
ever encountered an adverse event related to IOP rise. The
vast majority of surgeons (78.4%) had never encountered
one. An adverse event related to IOP rise is rare [20].
Assuming that each surgeon performs 400 cataract opera-
tions per year, and that the 20.2% surgeons who had
encountered the complications see it twice a year, the inci-
dence of this complication would be 0.1%. When the inci-
dence of any complication is this low, it may be difficult
to organise a randomised controlled trial to show if the
use of IOP lowering prophylaxis is effective or not, as the
sample size would run in tens of thousands. For example,
in this case, we would need 700,000 patients to be ran-
domised for a study with a power of 80%, to show a dif-
ference of 20% in the incidence of adverse event related to
IOP rise. This is clearly an impossible task. Randomised
controlled trials have been conducted to assess the role of
IOP prophylaxis [7-10,12-18], but they have used the IOP
level as a surrogate marker. There may be fluctuations in
the IOP levels, and a statistically significant difference
between the two groups, but whether this actually results
in a change in the incidence of an adverse event related to
IOP rise is unproven.
It was a weakness of our questionnaire that we did not ask
the surgeons about their annual cataract surgical volumes,
and the number of complications they had encountered.
Another point of this study that we would like to highlight
is that a high proportion of surgeons not prescribing rou-
tine IOP prophylaxis chose not to give a reason for the
basis of their practice.
Conclusion
In summary, this survey shows a very wide variation in
practice regarding postoperative management of patients
undergoing phacoemulsification with intraocular lens
implant. What is very striking is that there is a similar pro-
portion of surgeons in the diametrically opposite groups
(those who give or don't give routine IOP lowering proph-
ylaxis) who believe that their practice is evidence based.
Personal experience was cited by a large percentage of sur-
geons in each group. Practice of medicine is not necessar-
ily evidence based. Reasons include [22] clinical
experience, over-reliance on surrogate outcomes, ritual
and mystique. Our survey adds another explanation:
interpretation of the evidence in different ways, perhaps
to fit with one's clinical practice.
Whilst the authors would not wish to be prescriptive in
post PhIOL prophylaxis, the merits of this study suggests
further consideration might be given to drafting a uniform
guideline in this area of practice.
Appendix 1:
1) Do you routinely give any intraocular pressure lower-
ing agent to your patients (without co-morbidities) fol-
lowing  uncomplicated, phacoemulsification and lens
implant surgery?
a) Yes
b) No
2) If Yes, which one of the following?
a) Topical medication (Please specify the name of the
drug)
b) Oral Diamox- 250 mg/500 mg
3) At what stage following the surgery, do the patients
receive the above medication?
a) at the end of the surgical procedure
b) in the recovery area
c) on the ward
d) at home (after discharge from hospital)
4) How many doses are given?
Table 2
Timing of first postop IOP check No. of surgeons (n = 503) Surgeons who have experienced adverse events
Same day 55 (10.9%) 15 (27.2%)
1st post-op day 150 (29.7%) 25 (16.6%)
By first week 105 (20.8%) 20 (19.0%)
At 2 weeks 136 (26.9%) 36 (26.4%)
Beyond 2 weeks 48 (9.5%) 6 (12.5%)
Never 9 (1.8%) 0 (0%)
Legend: Relation between timing of first IOP check and reported experience with adverse events. There is no significant trend noticed.BMC Ophthalmology 2005, 5:24 http://www.biomedcentral.com/1471-2415/5/24
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a) one
b) two
c) three
5) What is the basis of your practice? (you may tick more
then one)
a) Based on evidence
b) Based on personal experience
c) Unit policy
6) Do you give subconjunctival injection at the end of the
procedure?
a) yes
b) no
7) If yes, which of the following ?
a) subconj antibiotic
b) subconj steroid
c) both
8) When do the patients have their intraocular pressure
checked for the first time after surgery?
a) Few hours after surgery
b) First postoperative day
c) 1 week postop
d) 2 weeks postop
9) Have you come across a sight threatening condition
caused by raised postoperative IOP?
a) Yes (please specify)
b) No
10) How would you treat a patient with significantly
raised IOP (> 30 mm Hg) within the first 24 hours follow-
ing surgery?
a) paracentesis through the 2nd port
b) oral diamox
c) I/V diamox
11) What post-op medication do you give to your patients
and for how long?
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